The ONLY monotherapy antidepressant that modulates
both glutamatergic and monoaminergic pathways1,2

SUBSTANTIAL symptom improvement that works1,3:
FAST
&
LASTS
What could MDD symptom improvement as early as Week 1 mean for your patients?

*Includes abnormal orgasm, erectile dysfunction, decreased libido, and anorgasmia.1

†Additional adverse reactions occurring in ≥2% of AUVELITY-treated patients and more frequently than in placebo-treated patients were nausea (13%); anxiety, constipation, decreased appetite, insomnia (at 4% each); arthralgia, fatigue (including lethargy), paresthesia (including hypoesthesia), and vision blurred (at 3% each).1

‡Terms and Conditions apply. Must have commercial insurance for savings program. Savings offer not available to patients with Medicare, Medicaid, or other government-funded insurance.

MDD=major depressive disorder.

Rapid, substantial symptom improvement
as early as Week 1, sustained at Week 61,3

Long-term safety and effectiveness data
measured up to 12 months4,5

The AUVELITY Patient Experience: data on
measures of quality of life, enjoyment, and function6

Demonstrated tolerability profile
The most common adverse events in the GEMINI 6-week study (≥5% and more than twice as frequently as placebo) were dizziness, headache, diarrhea, somnolence, dry mouth, sexual dysfunction,* and hyperhidrosis1,3†

Personalized support and savings with the Auvelity® OnMySide Program. Patients may pay as little as $10 for up to a 90-day prescription‡

Improved access nationwide, with 87% of patients now covered7

References